TLR8 and neoplasm: Another agonist of TLR7 and TLR8, namely R848 or resiquimod, loaded into β-cyclodextrin nanoparticles induced a functional re-orientation of the TME, in which the M2-like TAMs shifted toward a M1-like TAM phenotype, reducing tumor growth in multiple murine tumor models (56).